| Project/Area Number |
22KK0147
|
|---|
| Research Category |
Fund for the Promotion of Joint International Research (Fostering Joint International Research (B))
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Medium-sized Section 58:Society medicine, nursing, and related fields
|
|---|
| Research Institution | Nagasaki University |
|---|
Principal Investigator |
吉田 レイミント 長崎大学, 熱帯医学研究所, 教授 (90432963)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
樋泉 道子 長崎大学, 熱帯医学研究所, 准教授 (00778623)
柳原 克紀 長崎大学, 医歯薬学総合研究科(医学系), 教授 (40315239)
森内 浩幸 長崎大学, 医歯薬学総合研究科(医学系), 教授 (90315234)
|
|---|
| Project Period (FY) |
2022-10-07 – 2026-03-31
|
| Project Status |
Granted (Fiscal Year 2024)
|
| Budget Amount *help |
¥20,020,000 (Direct Cost: ¥15,400,000、Indirect Cost: ¥4,620,000)
Fiscal Year 2024: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2023: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
Fiscal Year 2022: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
|---|
| Keywords | HBV / HDV / HCV / genotype / drug resistant / Nigeria / Genotype / Drug resistance / Hepatitis B Virus / Hepatitis C Virus / Hepatitis D Virus / incidence / drug resistant variant / Viral hepatitis / therapeutic |
|---|
| Outline of Research at the Start |
DNA/RNA will be extracted from HBV and HCV positive serum samples stored at Nigeria CDC. PCR and sequencing will be performed to determine the genotype, drug resistant variants and predict optimal viral hepatitis therapeutic options. A rapid PCR based genotyping assays will be developed.
|
| Outline of Annual Research Achievements |
The main objective of the study was (i) to determine the patterns and prevalence of hepatitis B, C and D genotypes and circulating RAVs in Nigeria, and to predict the optimal VH therapeutic options for Nigeria. Upto now we have successfully processed and transported the DNA/RNA samples of hepatitis B, C and D samples for further testing to Nagasaki, Japan. We completed the HBV genotyping, drug resistant associated mutation analysis, and vaccine escape mutant analysis, and hepatitis D screening of the HBV positive samples. The study results has been published as Nigeria CDC PhD student's research paper (ref: Adewuyi O', et al. Molecular Epidemiology, Drug-Resistant Variants, and Therapeutic Implications of Hepatitis B Virus and Hepatitis D Virus Prevalence in Nigeria: A National Study. Pathogens. 2025 Jan 20;14(1):101). The Nigeria CDC PhD student graduated his PhD in 2025 March.
|
| Current Status of Research Progress |
Current Status of Research Progress
2: Research has progressed on the whole more than it was originally planned.
Reason
The study has been going on well but there was a delay is sample shipment from Nigeria to Nagasaki due to the COVID19 situation in Nigeria. Therefore, we have extended the study period to complete the genotyping and data analysis of HDV and HCV of the study. We aim to complete this in 2025 study period.
|
| Strategy for Future Research Activity |
We will conduct the whole genome sequencing experiment to determine the genotype, drug resistant variance of the HDV and HCV positive samples. The study results will be summarized (i) to presented at international meeting, and publication at peered reviewed journal.
|
